Protocol No.: D9722C00001
- Title
- A Randomised, Open-Label, Phase III Study of AZD5305 Plus Camizestrant versus Physician's Choice CDK4/6 Inhibitor Plus Endocrine Therapy for the First-Line Treatment of BRCA1, BRCA2, or PALB2-mutated Patients with Hormone Receptor-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH non-amplified) Advanced Breast Cancer (EvoPAR-Breast01)
- Principal Investigator
- Safi, Danish
- Phase
- III
- Age Group
- Adult
- Applicable Disease Site
- Breast Cancer
- Participating Institution
- Mary Babb Randolph Cancer Center
- Contact
- Emily Hawkins, BSN
- Research Nurse
- Phone: +1 304-293-7375
- Email: eswiger1@hsc.wvu.edu